Inventor
DUPLESSIS MARTIN
US30 patents
⚠️ This page may combine multiple inventors who share the name “DUPLESSIS MARTIN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
C4 THERAPEUTICS INC
9 patentsUS11459335B2Oct 4, 2022
N/O-linked Degrons and Degronimers for protein degradation
C4 THERAPEUTICS INC8 citations85
US12371442B2Jul 29, 2025
Isoindolinone and indazole compounds for the degradation of EGFR
C4 THERAPEUTICS INC1 citations74
US12048747B2Jul 30, 2024
Substituted piperidine Degronimers for Target Protein degradation
C4 THERAPEUTICS INC4 citations74
US11673902B2Jun 13, 2023
Isoindolinone and indazole compounds for the degradation of EGFR
C4 THERAPEUTICS INC3 citations72
US12486290B2Dec 2, 2025
Isoindolinone and indazole compounds for the degradation of EGFR
C4 THERAPEUTICS INC0 citations62
US12441740B2Oct 14, 2025
N/O-linked degrons and degronimers for protein degradation
C4 THERAPEUTICS INC0 citations62
US12180225B2Dec 31, 2024
N/O-linked degrons and degronimers for protein degradation
C4 THERAPEUTICS INC1 citations62
US12486253B2Dec 2, 2025
Therapeutics for the degradation of mutant BRAF
C4 THERAPEUTICS INC0 citations59
US12559492B2Feb 24, 2026
BRAF degraders
C4 THERAPEUTICS INC0 citations48
GENENTECH INC
6 patentsUS10308614B2Jun 4, 2019
Therapeutic compounds and uses thereof
GENENTECH INC4 citations73
US10239861B2Mar 26, 2019
Therapeutic compounds and uses thereof
GENENTECH INC2 citations72
US10358437B2Jul 23, 2019
Therapeutic compounds and uses thereof
GENENTECH INC0 citations41
US10301253B2May 28, 2019
Therapeutic compounds and uses thereof
GENENTECH INC0 citations41
US10202378B2Feb 12, 2019
Therapeutic compounds and uses thereof
GENENTECH INC0 citations41
US10155764B2Dec 18, 2018
Therapeutic compounds and uses thereof
GENENTECH INC0 citations40
CONSTELLATION PHARMACEUTICALS INC
5 patentsUS10016405B2Jul 10, 2018
Modulators of methyl modifying enzymes, compositions and uses thereof
CONSTELLATION PHARMACEUTICALS INC3 citations84
US9371331B2Jun 21, 2016
Modulators of methyl modifying enzymes, compositions and uses thereof
CONSTELLATION PHARMACEUTICALS INC8 citations83
US10526287B2Jan 7, 2020
LSD1 inhibitors and uses thereof
CONSTELLATION PHARMACEUTICALS INC2 citations73
US9980952B2May 29, 2018
Modulators of methyl modifying enzymes, compositions and uses thereof
CONSTELLATION PHARMACEUTICALS INC3 citations73
US9969716B2May 15, 2018
Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
CONSTELLATION PHARMACEUTICALS INC4 citations73
BOEHRINGER INGELHEIM INT
4 patentsUS8349839B2Jan 8, 2013
Inhibitors of HIV replication
BOEHRINGER INGELHEIM INT43 citations91
US9399645B2Jul 26, 2016
Inhibitors of HIV replication
BOEHRINGER INGELHEIM INT0 citations37
US9334249B2May 10, 2016
Inhibitors of cytomegalovirus
BOEHRINGER INGELHEIM INT0 citations37
US8039638B2Oct 18, 2011
Inhibitors of HIV replication
BOEHRINGER INGELHEIM INT0 citations37
HOFFMANN LA ROCHE
4 patentsUS12209091B2Jan 28, 2025
Isoindolinone derivatives as selective allosteric inhibitors of Egfr mutant cancers
HOFFMANN LA ROCHE7 citations85
US11708354B2Jul 25, 2023
2-benzopyrazinyl-n-heteroaryl-2-phenyl-acetamide compounds
HOFFMANN LA ROCHE3 citations72
US11117890B2Sep 14, 2021
Substituted isoindole allosteric EGFR inhibitors
HOFFMANN LA ROCHE3 citations72
US10882848B2Jan 5, 2021
2-benzopyrazinyl-n-heteroaryl-2-phenyl-acetamide compounds
HOFFMANN LA ROCHE3 citations72